The "Albumin Effect" and drug glucuronidation: Bovine serum albumin and fatty acid-free human serum albumin enhance the glucuronidation of UDP-glucuronosyltransferase (UGT) 1A9 substrates but not UGT1A1 and UGT1A6 activities

被引:136
作者
Rowland, Andrew
Knights, Kathleen M.
Mackenzie, Peter I.
Miners, John O.
机构
[1] Flinders Univ S Australia, Dept Clin Pharmacol, Adelaide, SA 5001, Australia
[2] Flinders Med Ctr, Adelaide, SA, Australia
关键词
D O I
10.1124/dmd.108.021105
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Bovine serum albumin (BSA) and fatty acid-free human serum albumin (HSAFAF) reduce the Km values for UGT2B7 substrates by sequestering inhibitory long-chain fatty acids released by incubations of human liver microsomes (HLM) and HEK293 cells expressing this enzyme. However, the scope of the "albumin effect" is unknown. In this investigation we characterized the effects of albumin on the kinetics of 4-methylumbelliferone (4MU) glucuronidation by UDP-glucuronosyltransferase (UGT) 1A1, 1A6, and 1A9, and propofol (PRO) glucuronidation by UGT1A9 and HLM. BSA and HSAFAF, but not human serum albumin, reduced the Km values for 4MU and PRO glucuronidation by UGT1A9. For example, HSAFAF (2%) reduced the Km values for 4MU and PRO glucuronidation from 13.4 to 2.9 and 41 to 7.2 mu M, respectively. Similarly, HSAFAF (2%) reduced the Km for PRO glucuronidation by HLM from 127 to 10.6 mu M. Arachidonic, linoleic, and oleic acids and a mixture of these decreased the rates of 4MU and PRO glucuronidation by UGT1A9. Km values for these reactions were increased 3- to 6-fold by the fatty acid mixture. Inhibition was reversed by the addition of BSA (2%). Extrapolation of kinetic constants for PRO glucuronidation by HLM in the presence of HSAFAF predicted in vivo hepatic clearance within 15%. Fatty acids had no effect on 4MU glucuronidation by UGT1A1 and UGT1A6 but, paradoxically, all forms of albumin altered the kinetic model for 4MU glucuronidation by UGT1A6 (from Michaelis-Menten to two-site). Only BSA caused a similar effect on 4MU glucuronidation by UGT1A1. It is concluded that BSA and HSAFAF reduce the Km values of only those enzymes inhibited by long-chain unsaturated fatty acids.
引用
收藏
页码:1056 / 1062
页数:7
相关论文
共 33 条
[1]   PHARMACOKINETICS OF PROPOFOL DURING AND AFTER LONG-TERM CONTINUOUS INFUSION FOR MAINTENANCE OF SEDATION IN ICU PATIENTS [J].
BAILIE, GR ;
COCKSHOTT, ID ;
DOUGLAS, EJ ;
BOWLES, BJM .
BRITISH JOURNAL OF ANAESTHESIA, 1992, 68 (05) :486-491
[2]   In vitro-in vivo correlations for drugs eliminated by glucuronidation:: Investigations with the model substrate zidovudine [J].
Boase, S ;
Miners, JO .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 54 (05) :493-503
[3]   S-Naproxen and desmethylnaproxen glucuronidation by human liver microsomes and recombinant human UDP-glucuronosyltransferases (UGT): role of UGT2B7 in the elimination of naproxen [J].
Bowalgaha, K ;
Elliot, DJ ;
Mackenzie, PI ;
Knights, KM ;
Swedmark, S ;
Miners, JO .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 60 (04) :423-433
[4]   Isoform-selective probe substrates for in vitro studies of human UDP-glucuronosyltransferases [J].
Court, MH .
PHASE II CONJUGATION ENZYMES AND TRANSPORT SYSTEMS, 2005, 400 :104-116
[5]   Evaluation of 3′-azido-3′-deoxythymidine, morphine, and codeine as probe substrates for UDP-glucuronosyltransferase 2B7 (UGT2B7) in human liver microsomes:: Specificity and influence of the UGT2B7*2 polymorphism [J].
Court, MH ;
Krishnaswamy, S ;
Hao, Q ;
Duan, SX ;
Patten, CJ ;
Von Moltke, LL ;
Greenblatt, DJ .
DRUG METABOLISM AND DISPOSITION, 2003, 31 (09) :1125-1133
[6]   Altered AZT (3′-azido-3′-deoxythymidine) glucuronidation kinetics in liver microsomes as an explanation for underprediction of in vivo clearance:: Comparison to hepatocytes and effect of incubation environment [J].
Engtrakul, JJ ;
Foti, RS ;
Strelevitz, TJ ;
Fisher, MB .
DRUG METABOLISM AND DISPOSITION, 2005, 33 (11) :1621-1627
[7]  
GEPTS E, 1987, ANESTH ANALG, V66, P1256
[8]  
Houston JB, 2000, DRUG METAB DISPOS, V28, P246
[9]  
HOUSTON JB, 1994, BIOCHEM PHARMACOL, V47, P1469
[10]   UDP-glucuronosyltransferases and clinical drug-drug interactions [J].
Kiang, TKL ;
Ensom, MHH ;
Chang, TKH .
PHARMACOLOGY & THERAPEUTICS, 2005, 106 (01) :97-132